A large cohort study found three popular GLP-1-based diabetes drugs — semaglutide, dulaglutide, and tirzepatide — carry similar risks for serious adverse GI events, with a rate of about 12 …
Copyright MatchingDonors.com © 2026 All rights reserved.
Daily Diabetes News is published by MatchingDonors.com.